Incyte’s Grip On Myelofibrosis Tightens With Release Of Positive JAK Data, FDA Filing

The profile and potential of Incyte Corp.’s ruxolitinib (INCB18424) in myelofibrosis came into sharper focus with the release of detailed data from two major trials at the American Society of Clinical Oncology meeting and announcement of an FDA filing.